A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia

Key Points

• The aim is to evaluate the effectiveness of basmisanil as an adjunctive treatment for cognitive impairment in schizophrenia.
• Conducted as a Phase 2b multicenter study
• Involved patients diagnosed with schizophrenia and cognitive impairment
• Administered basmisanil alongside standard treatments
• Measured cognitive performance and safety outcomes
• Basmisanil showed improvement in cognitive function measures
• Treatment was well-tolerated with manageable side effects
• Supported the potential for adjunctive therapy in schizophrenia management

Abstract